Linked Life Data

3907988

Source:http://linkedlifedata.com/resource/pubmed/id/3907988

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1986-2-20
pubmed:abstractText
A multi-centre, double-blind, randomized, placebo-controlled study was carried out to compare the efficacy and tolerance of sulindac (200 mg twice daily) with placebo in the symptomatic treatment for 7 days of 312 adult patients with upper respiratory tract infection. Investigators and patients rated sulindac superior to placebo in the overall evaluations of response to treatment, but the differences were not significant. In general, patients treated with sulindac had greater mean decreases from baseline scores for individual signs and symptoms than did placebo patients. Fever was relieved better by sulindac than by placebo. The mean decrease from baseline pain scores was also greater in the sulindac group. More patients receiving sulindac reported clinical adverse experiences compared with those on placebo, the most common adverse experiences reported being in the digestive system.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-7995
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
666-75
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
A multi-centre, double-blind randomized study to assess the efficacy and tolerance of sulindac versus placebo in the symptomatic treatment of patients with upper respiratory tract infection.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial